April 01, 1997; 48 (Suppl 5) Articles
Experience with IVIg in the treatment of patients with myasthenia gravis
Marinos C. Dalakas
First published April 1, 1997, DOI: https://doi.org/10.1212/WNL.48.Suppl_5.64S
Experience with IVIg in the treatment of patients with myasthenia gravis
Marinos C. Dalakas
Neurology Apr 1997, 48 (Suppl 5) 64S-69S; DOI: 10.1212/WNL.48.Suppl_5.64S
Citation Manager Formats
Make Comment
See Comments

Article Information
vol. 48 no. Suppl 5 64S-69S
Print ISSN:
Online ISSN:
History:
- First Published April 1, 1997.
Copyright & Usage:
Copyright 1997 by Advanstar Communications Inc.
Author Disclosures
- Marinos C. Dalakas, MD
- Marinos C. Dalakas, MD
- From the Nueromuscular Diseases Section, Medical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD.
- Address correspondence and reprint requests to Dr. Marinos C. Dalakas, NINDS, NIH, Building 10, Room 4N248, 10 Center Drive, MSC 1382, Bethesda, MD 20892-1382.
Article usage
Letters: Rapid online correspondence
No comments have been published for this article.
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Advertisement
Dr. Ann Yeh and Dr. Daniela Castillo Villagrán
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
Introduction
Myasthenia gravisHistorical perspective and overviewDavid S. Younger, Bradford B. Worrall, Audrey S. Penn et al.Neurology, April 01, 1997 -
Articles
Intravenous Immunoglobulin for the Treatment of Acquired Myasthenia GravisJames F. Howard, Jr. et al.Neurology, December 01, 1998 -
Articles
Mechanism of Action of Intravenous Immunoglobulin and Therapeutic Considerations in the Treatment of Autoimmune Neurologic DiseasesMarinos C. Dalakas et al.Neurology, December 01, 1998 -
Articles
Myasthenia in SCID mice grafted with myasthenic patient lymphocytesRole of CD4 and CD8 cellsZeng-Yu Wang, Peter I. Karachunski, James F. Howard, Jr. et al.Neurology, February 01, 1999